{"id":"tp-51695","type":"article-newspaper","title":"Allogene Targets Year-End 2027 Enrollment in ALPHA3 Study","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/51695","datePublished":"2026-11-08T16:51:18.000Z","dateModified":"2026-11-08T16:51:18.000Z","language":"en","abstract":"The company plans a clinical update around midyear, with interim analysis and any unblinding under DSMB oversight.","section":"Business","references":[]}